Record MS-N195 · Supportive care · Last literature search and appraisal: 31 October 2026

Evidence at a glance

• Evidence label: Dose-response signal; needs independent replication
• Potential benefit: A seven-arm randomized trial reported higher odds of a 30% improvement in a combined pain–fatigue–sleep score with longer massage sessions.
• Risk: Longer sessions may be burdensome; pressure and positioning must be adapted to frailty, bone metastases, skin injury, clot risk and devices.
• What this evidence is about: Palliative symptom relief, not cancer control.

What was studied

Two hundred seventy-three adults with cancer and all three symptoms were assigned across massage doses: 15, 30 or 60 minutes, two or three times weekly for four weeks, with four-week follow-up. Improvement was defined as at least a 30% reduction in the average 0–10 symptom-cluster score. Compared with the reference, reported odds ratios rose with duration: 4.36 (95% CI 0.94–20.32) for 15 minutes, 11.71 (2.60–52.69) for 30 minutes and 17.37 (3.87–77.90) for 60 minutes. More frequent sessions did not significantly improve odds, though durability was reported longer.

What the evidence cannot establish

Very wide confidence intervals, many arms, combined outcome, no inactive/sham control described in the abstract and setting-specific delivery make the apparent gradient uncertain. Appraisal was limited to the indexed abstract; full text was not verified. Registry IRCT20150302021307N5. Funding, conflicts, attrition and adverse events were not reported in the abstract.

Symptom improvement is not evidence of tumor shrinkage, delayed recurrence or longer survival. This record does not support replacing oncology treatment.

Practical safety context

Comfort and energy matter more than achieving a study “dose.” Stop for pain, dizziness, breathlessness, nausea, skin irritation or exhaustion. Do not massage directly over tumors, unstable bone lesions, thrombosis, infection, open wounds or sensitive devices.

Questions for the care team

• What symptom is the priority and how will a meaningful change be defined?
• What duration is tolerable given my energy and disease burden?
• Does the therapist have palliative-oncology experience and a plan for metastases or devices?

Sources checked

• Primary randomized dose trial (PMID 36226676)
• DOI 10.1177/02692163221129158
• Trial registry IRCT20150302021307N5

Source note: Publication dates refer to the indexed paper; links were checked on 31 October 2026. A registry entry verifies design or status, not efficacy. Unreported fields are not assumed to be absent.

Education only: This evidence summary is not personal medical advice. Decisions about symptoms, treatment interactions and complementary care belong with your oncology team.